文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension.

作者信息

Eirin Alfonso, Zhu Xiang-Yang, Ebrahimi Behzad, Krier James D, Riester Scott M, van Wijnen Andre J, Lerman Amir, Lerman Lilach O

机构信息

Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.

出版信息

Cell Transplant. 2015;24(10):2041-53. doi: 10.3727/096368914X685582. Epub 2014 Nov 21.


DOI:10.3727/096368914X685582
PMID:25420012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4440858/
Abstract

Renovascular hypertension (RVH) leads to left ventricular (LV) hypertrophy and diastolic dysfunction, associated with increased cardiovascular mortality. Intrarenal delivery of endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) improves kidney function in porcine RVH, and the potent anti-inflammatory properties of MSCs may serve to blunt inflammatory mediators in the cardiorenal axis. However, their relative efficacy in attenuating cardiac injury and dysfunction remains unknown. This study tested the hypothesis that the cardioprotective effect of EPCs and MSCs delivered into the stenotic kidney in experimental RVH are comparable. Pigs (n = 7 per group) were studied after 10 weeks of RVH or control untreated or treated with a single intrarenal infusion of autologous EPCs or MSCs 4 weeks earlier. Cardiac and renal function (fast CT) and stenotic kidney release of inflammatory mediators (ELISA) were assessed in vivo, and myocardial inflammation, remodeling, and fibrosis ex vivo. After 10 weeks of RVH, blood pressure was not altered in cell-treated groups, yet stenotic kidney glomerular filtration rate (GFR), blunted in RVH, improved in RVH + EPC, and normalized in RVH + MSCs. Stenotic kidney release of monocyte chemoattractant protein (MCP)-1 and its myocardial expression were elevated in RVH + EPC, but normalized only in RVH + MSC pigs. RVH-induced LV hypertrophy was normalized in both EPC- and MSC-treated pigs, while diastolic function (E/A ratio) was restored to normal levels exclusively in RVH + MSCs. RVH-induced myocardial fibrosis and collagen deposition decreased in RVH + EPCs but further decreased in RVH + MSC-treated pigs. Intrarenal delivery of EPCs or MSCs attenuates RVH-induced myocardial injury, yet MSCs restore diastolic function more effectively than EPCs, possibly by greater improvement in renal function or reduction of MCP-1 release from the stenotic kidney. These observations suggest a therapeutic potential for EPCs and MSCs in preserving the myocardium in chronic experimental RVH.

摘要

相似文献

[1]
Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension.

Cell Transplant. 2015

[2]
Intra-renal delivery of mesenchymal stem cells attenuates myocardial injury after reversal of hypertension in porcine renovascular disease.

Stem Cell Res Ther. 2015-1-19

[3]
Selective intrarenal delivery of mesenchymal stem cell-derived extracellular vesicles attenuates myocardial injury in experimental metabolic renovascular disease.

Basic Res Cardiol. 2020-1-14

[4]
IL-10 partly mediates the ability of MSC-derived extracellular vesicles to attenuate myocardial damage in experimental metabolic renovascular hypertension.

Front Immunol. 2022

[5]
Restoration of Mitochondrial Cardiolipin Attenuates Cardiac Damage in Swine Renovascular Hypertension.

J Am Heart Assoc. 2016-5-31

[6]
Autologous Extracellular Vesicles Attenuate Cardiac Injury in Experimental Atherosclerotic Renovascular Disease More Effectively Than Their Parent Mesenchymal Stem/Stromal Cells.

Stem Cell Rev Rep. 2023-4

[7]
Enhanced endothelial progenitor cell angiogenic potency, present in early experimental renovascular hypertension, deteriorates with disease duration.

J Hypertens. 2011-10

[8]
Endovascular reversal of renovascular hypertension blunts cardiac dysfunction and deformation in swine.

J Hypertens. 2021-3-1

[9]
Renovascular hypertension: Effects of mesenchymal stem cells in the contralateral hypertensive kidney in rats.

Clin Exp Hypertens. 2016-9-20

[10]
Human Obesity Attenuates Cardioprotection Conferred by Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells.

J Cardiovasc Transl Res. 2023-2

引用本文的文献

[1]
Advances in preclinical surgical therapy of cardiovascular diseases.

Int J Surg. 2024-8-1

[2]
The potential roles of exosomes in pathological cardiomyocyte hypertrophy mechanisms and therapy: A review.

Medicine (Baltimore). 2024-4-26

[3]
Research progress of extracellular vesicles and exosomes derived from mesenchymal stem cells in the treatment of oxidative stress-related diseases.

Front Immunol. 2023

[4]
Extracellular Vesicles and Pathological Cardiac Hypertrophy.

Adv Exp Med Biol. 2023

[5]
Body fluid-derived stem cells - an untapped stem cell source in genitourinary regeneration.

Nat Rev Urol. 2023-12

[6]
Obesity blunts amelioration of cardiac hypertrophy and fibrosis by human mesenchymal stem/stromal cell-derived extracellular vesicles.

Am J Physiol Heart Circ Physiol. 2023-7-1

[7]
Mesenchymal Stem Cells and Their Exocytotic Vesicles.

Int J Mol Sci. 2023-1-20

[8]
Autologous Extracellular Vesicles Attenuate Cardiac Injury in Experimental Atherosclerotic Renovascular Disease More Effectively Than Their Parent Mesenchymal Stem/Stromal Cells.

Stem Cell Rev Rep. 2023-4

[9]
Effects of mesenchymal stem cells in renovascular disease of preclinical and clinical studies: a systematic review and meta-analysis.

Sci Rep. 2022-10-27

[10]
Cardiovascular Effects of Autologous Bone Marrow-Derived Mesenchymal Stromal Cell Therapy With Early Tacrolimus Withdrawal in Renal Transplant Recipients: An Analysis of the Randomized TRITON Study.

J Am Heart Assoc. 2021-12-21

本文引用的文献

[1]
Extrarenal atherosclerotic disease blunts renal recovery in patients with renovascular hypertension.

J Hypertens. 2014-6

[2]
Stenting and medical therapy for atherosclerotic renal-artery stenosis.

N Engl J Med. 2013-11-18

[3]
Cardiac function in renovascular hypertensive patients with and without renal dysfunction.

Am J Hypertens. 2014-3

[4]
Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis.

Nephrol Dial Transplant. 2014-2

[5]
Mitochondrial targeted peptides attenuate residual myocardial damage after reversal of experimental renovascular hypertension.

J Hypertens. 2014-1

[6]
Mesenchymal stem cells improve medullary inflammation and fibrosis after revascularization of swine atherosclerotic renal artery stenosis.

PLoS One. 2013-7-3

[7]
C-kit(+) cells isolated from developing kidneys are a novel population of stem cells with regenerative potential.

Stem Cells. 2013-8

[8]
Endothelial outgrowth cells shift macrophage phenotype and improve kidney viability in swine renal artery stenosis.

Arterioscler Thromb Vasc Biol. 2013-2-21

[9]
Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms.

Stem Cells. 2013-1

[10]
Changes in glomerular filtration rate after renal revascularization correlate with microvascular hemodynamics and inflammation in Swine renal artery stenosis.

Circ Cardiovasc Interv. 2012-10-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索